Donepezil Hydrochloride Sandoz Ltd

Donepezil Hydrochloride Sandoz Ltd is a prescription medication containing the active ingredient donepezil hydrochloride, supplied by Sandoz Ltd. It is formulated for oral administration, though dosage form and strength are not disclosed. The product belongs to the acetylcholinesterase inhibitor class and is used in the management of cognitive symptoms associated with Alzheimer’s disease. Donepezil works by increasing acetylcholine levels in the brain, which may help improve memory and daily functioning.

Donepezil Hydrochloride is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease, aiming to support cognitive function and daily activities.

- Improves memory, attention, and language abilities in patients with early‑stage Alzheimer’s disease. - May help maintain the ability to perform everyday tasks such as dressing and cooking. - Used as part of a comprehensive care plan that includes non‑pharmacologic interventions. - Can be prescribed when cholinesterase inhibitor therapy is considered appropriate by a healthcare professional. - May be continued as disease progresses, provided tolerability and clinical benefit are assessed.

Side effects reported with Donepezil Hydrochloride vary in frequency and severity; they are categorized as common (typically mild) and serious (requiring medical attention).

Common: - Nausea, vomiting, or loss of appetite, especially when therapy is initiated. - Diarrhea or abdominal cramps that usually improve with continued use. - Insomnia or vivid dreams affecting sleep quality. - Muscle cramps or weakness, often transient. - Dizziness or light‑headedness, particularly after standing up quickly. - Headache that is mild to moderate in intensity.

Serious: - Severe bradycardia or heart block that may cause fainting. - Hepatotoxicity indicated by elevated liver enzymes or jaundice. - Allergic reactions such as rash, angioedema, or anaphylaxis. - Seizures or convulsions, though rare, may occur and need urgent evaluation. - Psychiatric symptoms such as agitation, depression, or hallucinations that worsen.

When prescribing Donepezil Hydrochloride, clinicians should consider several precautions to ensure patient safety and monitor for potential complications.

- Assess cardiac history, especially bradyarrhythmias, before initiating therapy. - Monitor liver function tests periodically, as hepatic impairment may increase drug exposure. - Use caution in patients with asthma or chronic obstructive pulmonary disease, as cholinergic effects may exacerbate bronchospasm. - Evaluate for gastrointestinal ulcer disease, since increased gastric secretions can aggravate existing lesions. - Review concomitant medications that may lower heart rate or interact with cytochrome P450 enzymes. - Consider dose adjustment in renal impairment, as excretion may be reduced. - Inform patients about the possibility of vivid dreams and advise them to report persistent sleep disturbances.

Donepezil Hydrochloride can interact with several medicines; understanding which combinations to avoid or use cautiously helps prevent adverse effects.

Avoid: - Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase plasma concentrations. - Combination with other cholinesterase inhibitors (e.g., rivastigmine) can lead to excessive cholinergic activity. - Co‑administration with drugs that cause bradycardia (e.g., beta‑blockers) may result in severe heart rate reduction.

Use with caution: - Anticholinergic agents (e.g., diphenhydramine) may diminish the therapeutic effect of donepezil. - Non‑steroidal anti‑inflammatory drugs can increase the risk of gastrointestinal bleeding when combined with donepezil. - Caution is advised when prescribing with anticoagulants, as donepezil may affect platelet function.